ArticleFrontiers in chemistry2026
Integrated docking-molecular dynamics, ADME-toxicity profiling, and transcriptomic validation identify oroxylin a as a TLR7-targeting flavonoid candidate in systemic lupus erythematosus.
Article in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic lupus erythematosus (SLE) remains difficult to control despite current therapies, highlighting the need for more selective, mechanism-based treatments targeting key innate immune components such as Toll-like receptor 7 (TLR7). Objectives: To identify natural flavonoid compounds with favorable stability and drug-like properties as hypothesis-generating TLR7 inhibitors for SLE using an integrated Methods: Six flavonoids (bavachinin, baicalein, apigenin, wogonin, eupalitin, and oroxylin A) were screened against TLR7 using molecular docking and 100-ns molecular dynamics simulations of the two top-scoring complexes. Drug likeness and ADME-toxicity were assessed using Results: Docking identified bavachinin and oroxylin A as the strongest initial binders to TLR7, while molecular dynamics showed that the oroxylin A-TLR7 complex exhibited greater conformational stability and more persistent interactions than bavachinin. Both ligands met drug-likeness criteria, but oroxylin A displayed a more balanced ADME-toxicity profile and less toxicity than the more lipophilic, immunotoxic bavachinin. KEGG enrichment of predicted oroxylin A targets highlighted inflammatory and immune-related pathways, and 12 predicted oroxylin A targets were consistently upregulated across both SLE datasets. Conclusion: Oroxylin A showed the most favorable combination of TLR7 complex stability, ADME-toxicity properties, immune-related pathway enrichment, and overlap with SLE-upregulated genes, supporting its prioritization as a potential TLR7-directed, hypothesis-generating candidate for SLE that warrants rigorous
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.